Business
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare special
About this update from Oric Pharmaceuticals, Inc.
[{"type":"image","alt":"ORIC Pharmaceuticals","displaySize":"","headline":null,"caption":"ORIC Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/dbfccbbaf8f622a31d2755c36eab59c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Hg7eXcFy4H7PFiEewv.fA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dbfccbbaf8f622a31d2755c36eab59c5","width":300,"height":85}},"lazy":false},{"type":"text","content":"Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors","length":224,"tagName":"p"},{"type":"text","content":"Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose","length":222,"tagName":"p"},{"type":"text","content":"Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study","length":219,"tagName":"p"},{"type":"text","content":"Expect to report multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential initiation of multiple registrational trials","length":155,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced operational highlights for 2025 and anticipated upcoming milestones.","length":322,"tagName":"p"},{"type":"text","content":"“2025 was a transformative and highly productive year for ORIC, marked by meaningful progress across our pipeline, including data that further strengthened our conviction in the potential best-in-class profiles of rinzimetostat in prostate cancer and enozertinib in lung cancer,” said Jacob M. Chacko, M.D., president and chief executive officer. “We also bolstered our leadership team and substantially extended our c...